Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Redcliffe Labs Announces Leadership Transition to Drive Healthcare Accessibility

Home
/
update
/
details

Lausanne Researchers Leverage 10x Genomics' Chromium and Xenium Technologies for New Insights into Brain Cancer Resistance and Therapeutic Opportunities

NextEdge Admin

11 Sep 2024

2 min 18 sec

10x Genomics, a leader in single-cell and spatial biology, announced the use of its Chromium Single Cell Gene Expression and Xenium In Situ platforms in a study published in *Cancer Cell*. Led by Professor Johanna Joyce of the University of Lausanne and Ludwig Institute for Cancer Research, the study explored how fibrotic scars contribute to glioblastoma (GBM) recurrence after treatment.

GBM is the most aggressive brain cancer, with a five-year survival rate of less than 5%. In this study, researchers discovered that all GBM treatments induced fibrosis in the brain, with recurrent tumors found adjacent to these scars. Dormant tumor cells within the scars were believed to act as seeds for recurrence. Using Chromium to analyze cell populations and Xenium to locate cells within the scars, the team identified pericyte-derived fibroblast-like cells as key drivers of scar formation.

Further analysis revealed two pathways linked to scar formation that peaked seven days post-treatment. The researchers developed a treatment combining a CSF-1R inhibitor and two drugs targeting scar formation, significantly improving survival rates in mice. Only one in 18 mice experienced recurrence during the trial.

Ben Hindson, Co-Founder of 10x Genomics, emphasized how integrating single-cell spatial and scRNA-seq technologies provided new insights into cancer dynamics, leading to potential therapeutic advancements. Professor Joyce highlighted the potential to enhance GBM patient outcomes by targeting fibrotic scarring, an area of ongoing research in her lab.